Alimera Sciences' ILUVIENĀ® Receives Final Draft Guidance From U.K.'s NICE

Alimera Sciences, a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that the United Kingdom's National Institute for Health and Clinical Excellence (N... [more]

View complete Press Release article